🧪
hypothesis

TREM2-dependent microglial phagocytosis of tau seeds

Hypothesis

TREM2-dependent microglial phagocytosis of tau seeds

Cystatin-C-activated TREM2 microglia reduce tau pathology through enhanced phagocytosis of extracellular tau seeds.
🧬 TREM2/Syk/PLCγ2🩺 neurodegeneration🎯 Composite 53%💱 $0.53▼1.9%proposed
EvidencePending (0%)📖 0 cit🗣 1 debates 7 support 2 oppose
✓ All Quality Gates Passed
Mechanistic 0.52 (15%) Evidence 0.50 (15%) Novelty 0.60 (12%) Feasibility 0.55 (12%) Impact 0.55 (12%) Druggability 0.50 (10%) Safety 0.55 (8%) Competition 0.55 (6%) Data Avail. 0.50 (5%) Reproducible 0.48 (5%) KG Connect 0.50 (8%) 0.530 composite
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite53%

🧪 Overview

Cystatin-C-activated TREM2 microglia reduce tau pathology through enhanced phagocytosis of extracellular tau seeds. Critical limitation: microglial phagocytosis can only address extracellular seeds, not intracellular neurofibrillary tangles. This severely limits therapeutic scope to disease prevention rather than modification of established pathology.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["Amyloid-beta Plaques<br/>Phospholipid Ligands"]
    B["TREM2 Receptor<br/>Ligand Binding"]
    C["TYROBP/DAP12<br/>ITAM Phosphorylation"]
    D["SYK Kinase<br/>Activation"]
    E["PLCG2<br/>IP3 + DAG Generation"]
    F["Ca2+ Release<br/>Cytoskeletal Remodeling"]
    G["Microglial Phagocytosis<br/>Plaque Compaction"]
    A --> B
    B --> C
    C --> D
    D --> E
    E --> F
    F --> G
    style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style G fill:#1b5e20,stroke:#81c784,color:#81c784

⚖️ Evidence

⚖️ Evidence Matrix7 supports2 contradicts
Supports
TREM2 loss-of-function accelerates tau pathology in human AD
PMID:29689295
Supports
Cystatin C colocalizes with amyloid plaques
PMID:26653636
Supports
Sleep deprivation exacerbates microglial reactivity and Aβ deposition in a TREM2-dependent manner in mice.
Sci Transl Med2023PMID:37099634
Supports
TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways.
Cell2022PMID:36306735
Supports
TREM2-dependent activation of microglial cell protects photoreceptor cell during retinal degeneration via PPARγ and CD36.
Cell Death Dis2024PMID:39187498
Supports
TREM2 dependent and independent functions of microglia in Alzheimer's disease.
Mol Neurodegener2022PMID:36564824
Supports
TREM2 Is a Receptor for β-Amyloid that Mediates Microglial Function.
Neuron2018PMID:29518356
Contradicts
TREM2 gain-of-function not demonstrated to reduce tau pathology
PMID:31776517
Contradicts
Extracellular tau seeds are only one pool; intracellular NFTs remain unaffected
PMID:NA
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — TREM2

🧬 PDB 6YXY Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for TREM2/Syk/PLCγ2 from GTEx v10.

Spinal cord cervical c-148.4 Substantia nigra20.7 Hypothalamus10.9 Hippocampus9.8 Amygdala8.9 Caudate basal ganglia7.9 Putamen basal ganglia6.6 Nucleus accumbens basal ganglia6.2 Anterior cingulate cortex BA245.6 Frontal Cortex BA95.1 Cortex3.5 Cerebellar Hemisphere2.9 Cerebellum1.5median TPM (GTEx v10)

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for TREM2 →

No DepMap CRISPR Chronos data found for TREM2.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

💰 Estimated Development
Cost
$0
Timeline

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0076
Events (7d)
1
Price History
▼1.9%

💾 Resource Usage

LLM Tokens
11,154
$0.0335
Total Cost
$0.0335

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF TREM2 is pharmacologically activated (via systemic administration of a TREM2 agonistic antibody at 10mg/kg twice weekly for 4 weeks) in 3-month-old P301S tauopathy mice, THEN extracellular tau seed≥50% reduction in extracellular tau seeds (seed-competent species detectable by RT-QuIC) within 4 weeks of TREM2 activation— no observation —pending0.60
IF TREM2 is activated (via cross-linked agonistic antibody) in primary microglia co-cultured with pre-formed tau fibrils, THEN intracellular aggregated tau will NOT decrease below baseline after 72 hoNo reduction in intracellular tau aggregates (<5% change) despite ≥2-fold enhancement of extracellular tau phagocytosis— no observation —pending0.55
🔮 Falsifiable Predictions (2)
pendingconf 60%
IF TREM2 is pharmacologically activated (via systemic administration of a TREM2 agonistic antibody at 10mg/kg twice weekly for 4 weeks) in 3-month-old P301S tauopathy mice, THEN extracellular tau seed levels will decrease by ≥50% compared to vehicle-treated controls, as measured by immunoprecipitati
Predicted outcome: ≥50% reduction in extracellular tau seeds (seed-competent species detectable by RT-QuIC) within 4 weeks of TREM2 activation
Falsification: No significant reduction (<20%) in extracellular tau seed levels despite confirmed TREM2 pathway engagement (p-Syk/PLCγ2 elevation); OR increase in extracellular tau seeds
pendingconf 55%
IF TREM2 is activated (via cross-linked agonistic antibody) in primary microglia co-cultured with pre-formed tau fibrils, THEN intracellular aggregated tau will NOT decrease below baseline after 72 hours, despite confirmed enhancement of phagocytosis (≥2-fold increase in pHrodo-labeled tau uptake),
Predicted outcome: No reduction in intracellular tau aggregates (<5% change) despite ≥2-fold enhancement of extracellular tau phagocytosis
Falsification: Significant reduction (>30%) in intracellular aggregated tau following TREM2 activation, indicating clearance of intracellular material contradicts the stated mechanism limitation
View on SciDEX ↗